[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-358358-105":59,"doc-detail-358358-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","european-code-against-cancer-5th-edition-organised-cancer-screening-programmes","European Code Against Cancer, 5th edition - organised cancer screening programmes","","The European Code Against Cancer, 5th edition (ECAC5) sets recommendations for sustainable, organised screening programmes across colorectal, breast, cervical and lung cancer. It specifies colorectal screening via biennial FIT for people aged 50–74, with one-time endoscopy as an alternative. Breast cancer guidance covers biennial digital mammography for ages 50–69, with possible extension for 45–49 and 70–74 and adjustments for high mammographic density. Cervical screening recommends HPV testing at intervals not shorter than 5 years for ages 30–65, adapted to vaccination status and screening history. Lung cancer screening is proposed with annual LDCT for increased-risk individuals and includes smoking cessation interventions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/european-code-against-cancer-5th-edition-organised-cancer-screening-programmes/358358/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/european-code-against-cancer-5th-edition-organised-cancer-screening-programmes/358358.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What colorectal cancer screening does ECAC5 recommend and for which age group?","Question",{"text":113,"@type":114},"ECAC5 recommends biennial quantitative faecal immunochemical test (FIT) for individuals aged 50–74. As an alternative within the same age range, once-only endoscopy may be considered.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does ECAC5 recommend breast cancer screening and how can it be adjusted?",{"text":118,"@type":114},"ECAC5 recommends biennial digital mammography for women aged 50–69. It notes that implementing the strategy for women aged 45–49 and 70–74 can be considered, and that additional considerations may be needed for those with high mammographic density.",{"name":120,"@type":111,"acceptedAnswer":121},"What cervical and lung cancer screening intervals does ECAC5 propose, and what else should be included?",{"text":122,"@type":114},"For cervical cancer, ECAC5 recommends HPV screening at intervals no shorter than 5 years for women aged 30–65, adapted to vaccination status and screening history. For lung cancer, it recommends annual low-dose computed tomography (LDCT) for individuals considered at increased risk, and screening should incorporate smoking cessation interventions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},358358,1790231851,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","POLICY PAPER  \nEuropean Code Against Cancer, 5th edition – organised cancer screening programmes  \nEsther Toes-Zoutendijk 1 , Marc Arbyn2, Anssi Auvinen3, David Baldwin4, Xavier Castells5, Andrea DeCensi6 , Solveig Hofvind7, Urska Ivanus8, Carlo Senore9, Mangesh Thorat 10,11 , Carlijn van der Aalst 1, Ana Carolina Pereira Nunes Pinto 12,13 , Javier Bracchiglione 12,13,14,15, Ariadna Feliu 16,17 , Hajo Zeeb 18,19, Erica D’Souza 16 , David Ritchie 16 , Carolina Espina 16 , Andre L. Carvalho 16 and Iris Lansdorp-Vogelaar 1  \n1 Public Health, Erasmus MC University Medical Centre, Rotterdam, Netherlands  \n2 Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium  \n3 Faculty of Social Sciences, Tampere University and Tampere University Hospital, Finland  \n4 Nottingham University Hospitals, Respiratory Medicine Unit, David Evans Centre, Nottingham City Hospital Campus, UK  \n5 Department of Epidemiology and Evaluation, Hospital del Mar Research Institute, Barcelona, Spain  \n6 EO Ospedali Galliera, Genoa, Italy  \n7 Department of Breast Cancer Screening, Cancer Registry, Norwegian Institute of Public Health, Oslo, Norway  \n8 Department of Cervical Cancer Screening, Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Slovenia  \n9 Epidemiology and screening unit – CPO, University hospital Citt della Salute e dela Scienza, Turin, Italy  \n10 Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, UK  \n11 Breast Services, Homerton University Hospital, London, UK  \n12 Iberoamerican Cochrane Centre, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain  \n13 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain  \n14 Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valpara 􀀃ıso, Vi~na del Mar, Chile  \n15 Centro de Investigacin Biomdica en Red de Epidemiolog 􀀃ıa y Salud Pblica, Instituto de Salud Carlos III, Madrid, Spain  \n16 International Agency for Research on Cancer (IARC/WHO), Lyon, France  \n17 Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK  \n18 Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany  \n19 Health Sciences, University of Bremen, Germany  \nKeywords  \nbreast cancer; cervical cancer; colorectal cancer; Europe; European Code Against Cancer; lung cancer; organised cancer screening; prostate  \nCorrespondence  \nE. Toes-Zoutendijk, Department of Public Health, Erasmus MC University Medical Center, P. O. Box 2014, Rotterdam 3000 CA, the Netherlands  \nTel: +31107038460  \nE-mail: [e.toes-zoutendijk@erasmusmc.nl](e.toes-zoutendijk@erasmusmc.nl)  \n(Received 24 July 2025, revised 31 October 2025, accepted 17 December 2025)  \nThe 5th edition of the European Code Against Cancer (ECAC5) recommends sustainable, organised screening programmes for: (a) colorectal cancer using biennial quantitative faecal immunochemical test (FIT) for individuals aged 50–74 years. As an alternative strategy, once-only endoscopy may be considered within the same age range; (b) breast cancer using biennial digital mammography for women aged 50–69 years. Implementing this strategy for women aged 45–49 years and 70–74 years can be considered. Other screening strategies or additional examinations could be considered for women with high mammographic density; (c) cervical cancer using human papillomavirus (HPV) screening at intervals no shorter than 5 years for women aged 30–65 years. It is recommended to adapt policies according to vaccination status and screening history; and (d) lung cancer using annual low-dose computed tomography (LDCT) for individuals considered to be at increased risk of lung cancer based on age, history of  \nAbbreviations  \nCEAs, Cost-effectiveness analyses; CIN3+, Cervical grade III intraepithelial neoplasia; COPD, Chronic obstructive pulmonary disease; ECAC, European Code Against Cancer; ECAC4, European Code Against Can","cbCaipOQVLJwJ6a1","https://ap.wps.com/l/cbCaipOQVLJwJ6a1","pdf",1672855,"English","# 1. Introduction\n## Objectives and epidemiological context\n## Core screening recommendations by cancer type\n## Smoking cessation and implementation considerations","[{\"question\":\"What colorectal cancer screening does ECAC5 recommend and for which age group?\",\"answer\":\"ECAC5 recommends biennial quantitative faecal immunochemical test (FIT) for individuals aged 50–74. As an alternative within the same age range, once-only endoscopy may be considered.\"},{\"question\":\"How does ECAC5 recommend breast cancer screening and how can it be adjusted?\",\"answer\":\"ECAC5 recommends biennial digital mammography for women aged 50–69. It notes that implementing the strategy for women aged 45–49 and 70–74 can be considered, and that additional considerations may be needed for those with high mammographic density.\"},{\"question\":\"What cervical and lung cancer screening intervals does ECAC5 propose, and what else should be included?\",\"answer\":\"For cervical cancer, ECAC5 recommends HPV screening at intervals no shorter than 5 years for women aged 30–65, adapted to vaccination status and screening history. For lung cancer, it recommends annual low-dose computed tomography (LDCT) for individuals considered at increased risk, and screening should incorporate smoking cessation interventions.\"}]","European Code Against Cancer, 5th edition - organised cancer screening programmes | PDF",1790133777]